124 related articles for article (PubMed ID: 10917374)
1. Use of rhDNase therapy and costs of respiratory-related care in patients with cystic fibrosis.
Ollendorf DA; McGarry LJ; Watrous ML; Oster G
Ann Pharmacother; 2000 Mar; 34(3):304-8. PubMed ID: 10917374
[TBL] [Abstract][Full Text] [Related]
2. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis.
Oster G; Huse DM; Lacey MJ; Regan MM; Fuchs HJ
Ann Pharmacother; 1995 May; 29(5):459-64. PubMed ID: 7655127
[TBL] [Abstract][Full Text] [Related]
3. [Socioeconomic evaluation of the effect of rhDNase on the cost of treating infections of the respiratory tract in patients with cystic fibrosis].
von der Schulenburg JM; Greiner W; von der Hardt H
Med Klin (Munich); 1995 Apr; 90(4):220-4. PubMed ID: 7776934
[TBL] [Abstract][Full Text] [Related]
4. Comment: cost of rhDNase in cystic fibrosis.
Marra CA; Carleton BC; Basmadjian D; Levine M; McKerrow R
Ann Pharmacother; 1995 Oct; 29(10):1050-1. PubMed ID: 8845550
[No Abstract] [Full Text] [Related]
5. rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease.
Christopher F; Chase D; Stein K; Milne R
J Clin Pharm Ther; 1999 Dec; 24(6):415-26. PubMed ID: 10651974
[TBL] [Abstract][Full Text] [Related]
6. Comment: cost of rhDNase in cystic fibrosis.
Bates RD; Nahata MC
Ann Pharmacother; 1995 Oct; 29(10):1051. PubMed ID: 8845551
[No Abstract] [Full Text] [Related]
7. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis.
Suri R; Grieve R; Normand C; Metcalfe C; Thompson S; Wallis C; Bush A
Thorax; 2002 Oct; 57(10):841-6. PubMed ID: 12324668
[TBL] [Abstract][Full Text] [Related]
8. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis.
Menzin J; Oster G; Davies L; Drummond MF; Greiner W; Lucioni C; Merot JL; Rossi F; vd Schulenburg JG; Souêtre E
Int J Technol Assess Health Care; 1996; 12(1):52-61. PubMed ID: 8690562
[TBL] [Abstract][Full Text] [Related]
9. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
Suri R; Marshall LJ; Wallis C; Metcalfe C; Bush A; Shute JK
Am J Respir Crit Care Med; 2002 Aug; 166(3):352-5. PubMed ID: 12153969
[TBL] [Abstract][Full Text] [Related]
10. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
11. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial.
Suri R; Metcalfe C; Lees B; Grieve R; Flather M; Normand C; Thompson S; Bush A; Wallis C
Lancet; 2001 Oct; 358(9290):1316-21. PubMed ID: 11684212
[TBL] [Abstract][Full Text] [Related]
12. rhDNase in cystic fibrosis.
Range SP; Knox AJ
Thorax; 1995 Apr; 50(4):321-2. PubMed ID: 7785000
[No Abstract] [Full Text] [Related]
13. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.
Shah PL; Scott SF; Fuchs HJ; Geddes DM; Hodson ME
Thorax; 1995 Apr; 50(4):333-8. PubMed ID: 7785003
[TBL] [Abstract][Full Text] [Related]
14. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.
Krauth C; Jalilvand N; Welte T; Busse R
Pharmacoeconomics; 2003; 21(14):1001-24. PubMed ID: 13129414
[TBL] [Abstract][Full Text] [Related]
15. Clinical studies of rhDNase in moderately and severely affected patients with cystic fibrosis--an overview.
Hodson ME
Respiration; 1995; 62 Suppl 1():29-32. PubMed ID: 7792438
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
Shah PI; Bush A; Canny GJ; Colin AA; Fuchs HJ; Geddes DM; Johnson CA; Light MC; Scott SF; Tullis DE
Eur Respir J; 1995 Jun; 8(6):954-8. PubMed ID: 7589382
[TBL] [Abstract][Full Text] [Related]
17. Retrospective review of the effects of rhDNase in children with cystic fibrosis.
Davies J; Trindade MT; Wallis C; Rosenthal M; Crawford O; Bush A
Pediatr Pulmonol; 1997 Apr; 23(4):243-8. PubMed ID: 9141109
[TBL] [Abstract][Full Text] [Related]
18. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
[TBL] [Abstract][Full Text] [Related]
19. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis.
Paul K; Rietschel E; Ballmann M; Griese M; Worlitzsch D; Shute J; Chen C; Schink T; Döring G; van Koningsbruggen S; Wahn U; Ratjen F;
Am J Respir Crit Care Med; 2004 Mar; 169(6):719-25. PubMed ID: 14684561
[TBL] [Abstract][Full Text] [Related]
20. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
